NICE approves new treatment for chronic heart failure
February 7, 2022Sales and Marketing
Empagliflozin (Jardiance®) has received a positive NICE recommendation for the treatment of chronic heart failure. NICE has announced that empagliflozin …
NICE recommends new combination for untreated advanced kidney cancer
February 4, 2022Medical Communications
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final …
NICE issues FAD for Forxiga in adults with chronic kidney disease
February 4, 2022Medical Communications
NICE has issued a Final Appraisal Document (FAD) recommending Forxiga (dapagliflozin) within its marketing authorisation for the treatment of adults …
Emmes supports new collaboration to advance COVID-19 research for children
February 4, 2022Medical Communications
Clinical research organisation, Emmes, announced its role as a Data Coordinating Center on a team whose work has accelerated paediatric …
University of Oxford: new HIV variant discovered
February 4, 2022A new and highly HIV variant with higher virulence, and more damaging health impacts, has been discovered in the Netherlands.In …
FDA orphan drug designation for treatment of rare blood cancer
February 3, 2022Business Services
The FDA has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS). The Office of …
Vaginal HRT tablets to become available over the counter
February 3, 2022Business Services
Vaginal oestrogen tablets, a type of hormone replacement therapy (HRT) – could become available in chemists soon, depending on the …
Illumina to advance precision medicine approach for late-stage cancer patients
February 3, 2022Business Services
Illumina announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University in France, to assess the clinical value …
CMA fines firms £35m for illegal arrangement
February 3, 2022Business Services
The Competition and Markets Authority (CMA) has fined firms over £35 million for an illegal arrangement in the supply of …
Novavax submits EUA to FDA for COVID-19 vaccine candidate
February 2, 2022Research and Development
Maryland-based Novavax has announced it is submitting an EUA request to the FDA, for its COVID-19 vaccine candidate.Novavax initially planned …
Omicron subvariant BA.2 likely to have same severity as ‘original’, says WHO
February 2, 2022Research and Development
The BA.2 form of the Omicron coronavirus variant is unlikely to be any more severe than the original BA.1 form, …
FDA approval of six-annual-dose HIV treatment
February 2, 2022Research and Development
ViiV Healthcare has announced the FDA approval of Cabenuva (cabotegravir, rilpivirine) for every-two-month dosing for
First European filing submission for multiple myeloma bispecific antibody
February 2, 2022Research and Development
Janssen has announced the submission of a Marketing Authorisation Application (MAA) to the EMA, seeking approval for off-the-shelf-bispecific antibody teclistamab, …
Technology on trial – the latest cogs in the clinical machine
February 1, 2022From the integration of social media to everyday life, to the seeping of AI into our daily lives, the past …
Access denied: Is Brexit spelling bedlam for UK clinical trials?
February 1, 2022Since Article 50 was triggered on the 29 March 2017, the UK’s pharmaceutical industry collectively held its breath, bracing itself …
Measles jab rate in England falls to ten percent below recommended rate
February 1, 2022Medical Communications
Over one in 10 school entry-age children in England are at risk of measles due to not receiving their vaccine …
AI technology has the potential for breast cancer diagnosis
February 1, 2022Manufacturing and Production
Academics at King’s College, London, and Guy’s and St Thomas’ NHS Foundation Trust, are using historical scans in a new …
WHO: COVID-19 hospital waste presents health threat
February 1, 2022Manufacturing and Production
The vast amount of waste produced in tackling the COVID-19 pandemic poses a threat to human and environmental health, warns …
RDIF, AstraZeneca and others invest in treatments for resistant arterial hypertension
February 1, 2022Medical Communications
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), AstraZeneca, and Unicorn Capital Partners, a biotech-specialised VC fund, announced …
FDA approves Vabysmo to treat vision-threatening retinal conditions
January 31, 2022Sales and Marketing
The FDA has approved vabysmo (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration and diabetic macular edema. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
